The primary patent for Pradaxa (dabigatran etexilate mesylate), a medication used to prevent stroke and systemic embolism in certain patients with atrial fibrillation, is set to expire in 2029 in the United States [1].
When does Pradaxa exclusivity end?
While the main patent expires in 2029, other forms of market exclusivity, such as those related to pediatric exclusivity or specific formulations, could extend beyond this date. Regulatory exclusivities can sometimes run concurrently or sequentially with patent protection.
Are there other patents for Pradaxa?
In addition to the primary patent that expires in 2029, there may be secondary patents covering different aspects of Pradaxa, such as manufacturing processes, specific polymorphs, or therapeutic uses. These secondary patents could have different expiration dates, potentially extending the period of protection for the drug manufacturer. DrugPatentWatch.com tracks these patent filings and their expiration timelines [1].
What happens after Pradaxa's patents expire?
Following the expiration of Pradaxa's patents and any associated exclusivity periods, generic versions of dabigatran etexilate mesylate may become available. This typically leads to a significant decrease in drug prices, as generic manufacturers can offer more affordable alternatives.
How does Pradaxa compare to other anticoagulants?
Pradaxa belongs to a class of drugs known as direct oral anticoagulants (DOACs), which also include rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa). These drugs are often compared based on their efficacy, safety profiles (particularly bleeding risks), dosing regimens, and cost. Unlike warfarin, DOACs generally do not require routine blood monitoring, though monitoring may be necessary in specific clinical situations.
Who makes Pradaxa?
Pradaxa was developed and is marketed by Boehringer Ingelheim [2].
What is the generic name for Pradaxa?
The generic name for Pradaxa is dabigatran etexilate mesylate [1].